Wall Street brokerages expect that Radius Health, Inc. (NASDAQ:RDUS) will report earnings per share (EPS) of ($1.40) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Radius Health’s earnings. The lowest EPS estimate is ($1.56) and the highest is ($1.05). Radius Health reported earnings per share of ($1.22) during the same quarter last year, which suggests a negative year over year growth rate of 14.8%. The business is expected to issue its next earnings report on Thursday, February 22nd.
On average, analysts expect that Radius Health will report full-year earnings of ($5.40) per share for the current year, with EPS estimates ranging from ($5.77) to ($4.52). For the next year, analysts anticipate that the business will post earnings of ($4.77) per share, with EPS estimates ranging from ($5.98) to ($3.52). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Radius Health.
Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period last year, the business earned ($1.07) EPS.
Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $58.00 target price on shares of Radius Health in a research note on Friday, November 3rd. Jefferies Group LLC decreased their target price on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $45.00 target price on shares of Radius Health in a research note on Friday, October 6th. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, Maxim Group reiterated a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Radius Health has a consensus rating of “Hold” and an average target price of $51.00.
Shares of Radius Health (NASDAQ RDUS) traded down $0.39 on Friday, hitting $27.71. 1,645,900 shares of the stock traded hands, compared to its average volume of 964,848. Radius Health has a twelve month low of $27.16 and a twelve month high of $55.97. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.
In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction that occurred on Tuesday, September 5th. The stock was purchased at an average price of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the transaction, the insider now directly owns 5,298,799 shares in the company, valued at $194,730,863.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of Radius Health stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average price of $28.09 per share, with a total value of $49,944.02. Following the transaction, the vice president now owns 2,278 shares of the company’s stock, valued at $63,989.02. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 427,678 shares of company stock valued at $14,430,298. 15.00% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of RDUS. Principal Financial Group Inc. increased its holdings in Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 180 shares in the last quarter. Teachers Advisors LLC increased its holdings in Radius Health by 4.4% in the first quarter. Teachers Advisors LLC now owns 54,024 shares of the biopharmaceutical company’s stock valued at $2,088,000 after buying an additional 2,289 shares in the last quarter. Vanguard Group Inc. increased its holdings in Radius Health by 3.2% in the first quarter. Vanguard Group Inc. now owns 3,010,646 shares of the biopharmaceutical company’s stock valued at $116,362,000 after buying an additional 93,188 shares in the last quarter. Geode Capital Management LLC increased its holdings in Radius Health by 6.8% in the first quarter. Geode Capital Management LLC now owns 299,263 shares of the biopharmaceutical company’s stock valued at $11,566,000 after buying an additional 19,085 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after buying an additional 2,628,070 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: “-$1.40 Earnings Per Share Expected for Radius Health, Inc. (RDUS) This Quarter” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/11/14/1-40-earnings-per-share-expected-for-radius-health-inc-rdus-this-quarter.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.